



中國生物製藥有限公司
SINO BIOPHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立之有限公司)
(Stock Code 股份代號: 1177)

NOTIFICATION LETTER 通知信函

29 April 2025

Dear Registered Shareholders,

Sino Biopharmaceutical Limited (the “Company”)

– Notice of publication of (i) 2024 Annual Report and (ii) Circular in relation to general mandates to issue and buy back shares; re-election of Directors; adoption of the new articles; and notice of annual general meeting, and (iii) Form of proxy of the Company (collectively the “Current Corporate Communication”)

The English and Chinese versions of the Company’s Current Corporate Communication are now available on the Company’s website at www.sinobiopharm.com and the website of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) at www.hkexnews.hk respectively (the “Website Version”). The Company strongly recommends you to access the Website Version of the Current Corporate Communication and all future Corporate Communications ^(Note). If you have elected to receive the Corporate Communications in printed form, the Current Corporate Communication is enclosed.

If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company’s branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited (the “Branch Share Registrar”) at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mailing label (no stamp is needed if posted in Hong Kong) or by email to is-ecom@vistra.com. The Company will promptly upon your request send the Current Corporate Communication to you in printed form free of charge.

It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning it to the Branch Share Registrar at the above-mentioned address by post or by email to is-ecom@vistra.com. If the Company does not have your functional email address, until such time that the functional email address is provided to the Branch Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications (“Notice of Publication”) and Actionable Corporate Communications in electronic form. As such, the Company would only be able to send you the Notice of Publication and the Actionable Corporate Communications in printed form.

Should you have any queries relating to this notification, please call the Branch Share Registrar’s telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m., Monday to Friday (excluding public holidays).

Yours faithfully,

For and on behalf of

Sino Biopharmaceutical Limited

Chan Oi Nin Derek

Company Secretary

Note: Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors’ report and its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) Actionable Corporate Communications.

Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.

各位登記股東：

中國生物製藥有限公司（「本公司」）

– (i)二零二四年年報及(ii)有關發行及回購股份之一般授權、重選董事、採納新章程細則及股東週年大會通告的通函，以及(iii)代表委任表格（統稱「本次公司通訊」）之登載通知

本公司的本次公司通訊的中、英文版本已分別上載於本公司網站(www.sinobiopharm.com)及香港聯合交易所有限公司（「聯交所」）的網站(www.hkexnews.hk)（「網站版本」）。我們建議閣下閱覽本公司本次公司通訊及日後公司通訊^(附註)的網站版本。如閣下已選擇收取公司通訊的印刷本，隨函附上本次公司通訊。

如閣下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本，及欲索取本次公司通訊及日後公司通訊的印刷本，請填妥及簽署隨附的回條，並以已預付郵費的郵寄標籤寄回本公司的香港股份過戶登記分處（「股份過戶登記分處」）卓佳證券登記有限公司（地址為香港夏慤道16號遠東金融中心17樓）（如在香港投寄毋須貼上郵票），或電郵至 is-ecom@vistra.com。本公司會因應閣下的要求立即寄上本次公司通訊的印刷本，費用全免。

登記股東有責任提供有效的電子郵件地址。如閣下尚未提供閣下的電子郵件地址予本公司，或需更新閣下的電子郵件地址，本公司建議閣下填妥及簽署隨附的回條，並按上述地址以郵寄方式交回本公司的股份過戶登記分處或以電郵方式發送至 is-ecom@vistra.com。如果本公司沒有收到閣下的有效電子郵件地址，直至股份過戶登記分處收到閣下有效的電子郵件地址前，閣下將無法透過電子郵件方式收取以電子方式發送的公司通訊網站版本的登載通知（「登載通知」）及可供採取行動的公司通訊。本公司只能以印刷本方式發送登載通知及可供採取行動的公司通訊予閣下。

倘閣下對本通知有任何查詢，請於辦公時間星期一至星期五（公眾假期除外）上午9時至下午6時，致電股份過戶登記分處熱線(852) 2980 1333。

代表

中國生物製藥有限公司

公司秘書

陳凱年

謹啟

2025年4月29日

附註：公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件，其中包括但不限於 (a) 董事會報告及公司年度帳目連同核數師報告以及財務摘要報告（如適用）；(b) 中期報告及中期摘要報告（如適用）；(c) 會議通告；(d) 上市文件；(e) 通函；(f) 代表委任表格；及 (g) 可供採取行動的公司通訊。

可供採取行動的公司通訊是指任何涉及要求股東指示其作為股東擬如何行使有關權利或作出選擇的公司通訊。

Registered Shareholder's information (English name and address)
登記股東資料（英文姓名及地址）

REPLY FORM 回條

To: **Sino Biopharmaceutical Limited**
(the “Company”) (Stock Code: 1177)
(Incorporated in the Cayman Islands with limited liability)
c/o Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road, Hong Kong

致： 中國生物製藥有限公司
（「本公司」）（股份代號：1177）
（於開曼群島註冊成立之有限公司）
經卓佳證券登記有限公司
香港夏慤道16號
遠東金融中心17樓

Part A 甲部	I/We would like to receive the Current Corporate Communication and all future Corporate Communications in printed form in the manner indicated below: 本人/我們現欲以以下方式收取本次公司通訊及日後所有公司通訊的印刷本：
--------------	---

(Please mark “✓” in **ONLY ONE** of the following boxes 請從下列選擇中，僅在其中一個空格內劃上「✓」號)

☐ I/We would like to receive a printed copy **in the English language only**; OR
本人／我們現欲收取一份英文印刷本；或

☐ I/We would like to receive a printed copy **in the Chinese language only**; OR
本人／我們現欲收取一份中文印刷本；或

☐ I/We would like to receive a printed copy **in both the English language and the Chinese language**.
本人／我們現欲收取英文和中文各一份印刷本。

Part B 乙部	I/We would like to receive the notices of publication of all future Corporate Communications and Actionable Corporate Communications in electronic form via the email address below: 本人／我們現欲以以下電子郵件地址以電子方式收取本公司日後所有公司通訊的登載通知及可供採取行動的公司通訊：
--------------	---

[illegible]

Name(s) of Shareholder(s): 股東姓名:	(Please use English BLOCK LETTERS) (請用英文正楷填寫)	Signature: 簽名:	
Address: 地址:			(Please use English BLOCK LETTERS) (請用英文正楷填寫)
Contact telephone number: 聯絡電話號碼:		Date: 日期:	

Notes 附註：

1. Please complete and sign this Reply Form and return it by cutting and sticking the prepaid mailing label on an envelope to the Company's branch share registrar and transfer office in Hong Kong, Tricor Investor Services Limited or via email to is-ecom@vistra.com.
請填妥及簽署本回條，並以隨附之預付郵費的郵寄標籤貼於信封上，寄回本公司的香港股份過戶登記處卓佳證券登記有限公司，或電郵至 is-ecom@vistra.com。
2. Please complete this Reply Form clearly. Any form with no indicated choice, with no signature or otherwise incorrectly completed shall be void. If your shares are held in joint names, the shareholder whose name stands first on the register of members of the Company is responsible of the joint holding should sign this Reply Form in order to be valid.
請清楚填寫本回條，回條上若未有作出選擇，沒有簽名或沒有正確地填寫，均屬無效。如屬聯名股東，則本回條須按本公司股東名冊上聯名持有的股份戶口，由其姓名列於首位的股東簽署，方為有效。
3. The above instruction for part A will apply to all future Corporate Communications to be sent to you until you notify otherwise by reasonable notice in writing to the Branch Share Registrar or until expired at the end of each financial year of the Company (whichever is earlier). Further request in writing will be required if a shareholder prefers to continue receiving printed copy of future Corporate Communications.
上述甲部指示適用於本公司日後向閣下發佈的所有公司通訊，直至閣下以合理時間書面通知股份過戶登記處更改有關指示或直至本公司各財政年度末到期（以較早者為準）。如果股東希望繼續收到日後的公司通訊的印刷本，則需要做進一步書面請求。
4. If both English and Chinese versions of the Corporate Communications are combined into one document, a printed form of the Corporate Communications with both English and Chinese versions will be sent to the Shareholder requesting for a printed form of any version(s) of the Corporate Communications.
若公司通訊的英文版本及中文版本合供為一份文件，則一份載有公司通訊的英文版本及中文版本的印刷版本將寄給要求索取任一版本公司通訊印刷版本的股東。
5. If the Company does not press the email address of a Shareholder or the email address provided is not functional, such Shareholder will be deemed, until such time when such Shareholder has provided a valid and functional email address to the Branch Share Registrar, to have elected to receive a notice of publication of the Corporate Communications by post.
倘若公司並無提供或電子郵件地址或所提供之電子郵件地址無效，則該股東將被視為已選擇以郵寄方式接收公司通訊網站版的通知，直至該股東向股份過戶登記處提供有效且可用的電子郵件地址為止。
6. For the avoidance of doubt, we do not accept any other special instructions written on this Reply Form.
為免存疑，本公司概不接受於本回條上書寫的任何其他特別指示。
7. Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; (f) a proxy form; and (g) Actionable Corporate Communications.
公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件，其中包括但不限於 (a) 董事會報告及公司年度帳目連同該數師報告以及財務摘要報告（如適用）；(b) 中期報告及中期摘要報告（如適用）；(c) 會議通告；(d) 上市文件；(e) 通函；(f) 代表委任表格；及 (g) 可供採取行動的公司通訊。
8. Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.
可供採取行動的公司通訊是指任何涉及要求股東指示其作為股東擬如何行使有關股東權利或作出選擇的公司通訊。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

“Personal Data” in this statement has the same meaning as “personal data” defined in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong (“PDPO”). Your supply of the Personal Data is on a voluntary basis and for the purpose of processing your instructions as stated in this Reply Form (the “Purposes”). If you fail to supply sufficient information, the Company may not be able to process your instructions. The Company may disclose or transfer the Personal Data to its subsidiaries, its Branch Share Registrar and/or third party service provider who provides administrative, computer and other services to the Company for use in connection with the Purposes and to such parties who are authorised by law to request the information or are otherwise relevant for the Purposes and need to receive the information. The Personal Data will be retained for such period as may be necessary to fulfill the Purposes (including for verification and record purposes). Request for access to and/or correction of the Personal Data can be made in accordance with the provisions of the PDPO and any such request should be in writing and sent to the Data Privacy Officer of Tiscor Investor Services Limited at the above address.

「個人資料」在此聲明具有與《個人資料(私隱)條例》(「PDPO」)所界定的「個人資料」相同的涵義。閣下提供個人資料是基於自願性質，且僅為處理閣下的指示。倘若閣下未能提供足夠資料，則本公司可能無法處理閣下的指示。本公司可能會將個人資料披露或轉予其附屬公司、其股份過戶登記處及/或為本公司提供行政、電腦及其他服務的供應商，以及根據其他法律授權而可取得有關資料的人士及其他上述的該等用途有關及需要接收有關資料之人士。個人資料將在適當期間保留以履行上述資料的該等用途(包括核實及紀錄用途)。有關閱覽及/或更正個人資料的要求可按照《個人資料(私隱)條例》提出，而有關要求須以書面方式寄出至卓卓證券登記有限公司(地址如上)的個人資料專員處。

Please cut the mailing label and stick it on an envelope to return this Reply Form to us.
No postage is necessary if posted in Hong Kong.

當閣下寄回本回條時，請將郵寄標籤剪貼於信封上。
如在本港投寄，閣下無需支付郵費或貼上郵票。

Mailing Label 郵寄標籤

Tricor Investor Services Limited
卓佳證券登記有限公司
Freepost No. 簡便回郵號碼：10 GPO
Hong Kong 香港